News for Otonomy, Inc. (OTIC)

**media[535226,535227]**

Sensorineural hearing loss (SNHL) is the most common type of hearing loss, caused by damage to the inner ear (cochlea) or the auditory nerve pathways....

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

/PRNewswire/ -- The vertigo drugs market size is expected to grow by USD 551.42 million from 2022 to 2027. In addition, the momentum of the market will...

/PRNewswire/ -- The "Hearing Loss Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Product , By Disease Type, By End-User, By Region,...

REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of...

Alluvial Fund began the year, rising 3.6% vs. Russell 2000 Index gained 2.7% and Russell Micro-Cap Index fell 2.8%. Click here to read the full fund letter.

/PRNewswire/ -- According to Technavio, the global ear infection treatment market size is estimated to grow by USD 3.67 billion from 2021 to 2026. The market...

Elk Capital Markets UK has disclosed ownership of 8.3% of Otonomy stock.

NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, unit, and warrant of Tuscan...

Nasdaq has sent a letter to Otonomy (OTIC) indicating that the company's shares would be suspended from trading on the stock exchange.

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was ...

(RTTNews) - Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S ...

Shares of Otonomy Inc. undefined plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's...

Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for ...

Otonomy, Inc. (NASDAQ:OTIC) Q4 2020 Earnings Conference Call February 11, 2021 16:30 ET Company Participants Robert Uhl - Investor Relations David Weber - President and Chief Executive...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X ...

Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX:BRG) is expected to report quarterly ...